Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T cells to
directly recognize and kill tumour cells,–. These strategies are limited by the emergence of …

Single-cell omics aim at charting the different types and properties of all cells in the human
body in health and disease. Over the past years, myriads of cellular phenotypes have been …

Tumour-associated macrophages (TAMs) are essential players in the tumour
microenvironment (TME) and modulate various pro-tumorigenic functions such as …

Background Recent advances in digital pathology have enabled accurate and standardised
enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a …

The tumor microenvironment (TME) constitutes a complex microenvironment comprising a
diverse array of immune cells and stromal components. Within this intricate context, tumor …

An important challenge in the real-world management of patients with advanced clear-cell
renal cell carcinoma (aRCC) is determining who might benefit from immune checkpoint …

Solid tumours comprise many different cell types organized in spatially structured
arrangements, with substantial intratumour and intertumour heterogeneity. Advances in …

The growth and metastasis of solid tumours is known to be facilitated by the tumour
microenvironment (TME), which is composed of a highly diverse collection of cell types that …

Enabling the examination of cell-cell relationships in tissue, spatially resolved omics
technologies have revolutionised our perspectives on cancer biology. Clinically, the …

Introduction Combination immunotherapy holds promise for improving survival in responsive
glioblastoma (GBM) patients. Programmed death-ligand 1 (PD-L1) expression in immune …